Innovative Device Designation (创新医疗器械)
This page provides a plain English reference for innovative device designation (创新医疗器械) under China's NMPA regulatory framework. Full content to be completed during editorial review.
Regulatory basis
Special access and designation pathways are established under NMPA orders and announcements. See What's New for the latest updates to these programmes.
Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official NMPA sources before making regulatory decisions. Not affiliated with NMPA or any Chinese Government body. Not legal or regulatory advice.
Add a complete section explaining: (1) definition of 'innovative' under NMPA criteria; (2) eligibility requirements (novel technology, significant clinical benefit, no equivalent in China); (3) application process and required evidence; (4) benefits of designation (shortened review timelines, expedited CMDE review, priority consideration); (5) reference NMPA Announcement 75 (2018) or latest relevant order; (6) typical review timelines post-designation; (7) transition from designated to standard product status.